☰

Jan van de Winkel - Publications

Affiliations: 
Immunology University Medical Center Utrecht, Utrecht, Netherlands 
Area:
Immunotherapy
Tree Info Similar researchers PubMed Report error

51/112 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2016 Kellner C, Günther A, Humpe A, Repp R, Klausz K, Derer S, Valerius T, Ritgen M, Brüggemann M, van de Winkel JG, Parren PW, Kneba M, Gramatzki M, Peipp M. Enhancing natural killer cell-mediated lysis of lymphoma cells by combining therapeutic antibodies with CD20-specific immunoligands engaging NKG2D or NKp30. Oncoimmunology. 5: e1058459. PMID 26942070 DOI: 10.1080/2162402X.2015.1058459  0.339
2014 Diebolder CA, Beurskens FJ, de Jong RN, Koning RI, Strumane K, Lindorfer MA, Voorhorst M, Ugurlar D, Rosati S, Heck AJ, van de Winkel JG, Wilson IA, Koster AJ, Taylor RP, Saphire EO, et al. Complement is activated by IgG hexamers assembled at the cell surface. Science (New York, N.Y.). 343: 1260-3. PMID 24626930 DOI: 10.1126/Science.1248943  0.509
2013 Boross P, Lohse S, Nederend M, Jansen JH, van Tetering G, Dechant M, Peipp M, Royle L, Liew LP, Boon L, van Rooijen N, Bleeker WK, Parren PW, van de Winkel JG, Valerius T, et al. IgA EGFR antibodies mediate tumour killing in vivo. Embo Molecular Medicine. 5: 1213-26. PMID 23918228 DOI: 10.1002/emmm.201201929  0.401
2013 Stemerding AM, Köhl J, Pandey MK, Kuipers A, Leusen JH, Boross P, Nederend M, Vidarsson G, Weersink AY, van de Winkel JG, van Kessel KP, van Strijp JA. Staphylococcus aureus formyl peptide receptor-like 1 inhibitor (FLIPr) and its homologue FLIPr-like are potent FcγR antagonists that inhibit IgG-mediated effector functions. Journal of Immunology (Baltimore, Md. : 1950). 191: 353-62. PMID 23740955 DOI: 10.4049/jimmunol.1203243  0.348
2013 Labrijn AF, Meesters JI, De Goeij BECG, Van Den Bremer ETJ, Neijssen J, Van Kampen MD, Strumane K, Verploegen S, Kundu A, Gramer MJ, Van Berkel PHC, Van De Winkel JGJ, Schuurman J, Parren PWHI. Efficient generation of stable bispecific IgG1 by controlled Fab-arm exchange Proceedings of the National Academy of Sciences of the United States of America. 110: 5145-5150. PMID 23479652 DOI: 10.1073/pnas.1220145110  0.44
2011 Boross P, Jansen JH, de Haij S, Beurskens FJ, van der Poel CE, Bevaart L, Nederend M, Golay J, van de Winkel JG, Parren PW, Leusen JH. The in vivo mechanism of action of CD20 monoclonal antibodies depends on local tumor burden. Haematologica. 96: 1822-30. PMID 21880632 DOI: 10.3324/haematol.2011.047159  0.367
2011 Overdijk MB, Verploegen S, Van Den Brakel JH, Lammerts Van Bueren JJ, Vink T, Van De Winkel JGJ, Parren PWHI, Bleeker WK. Epidermal growth factor receptor (EGFR) Antibody-induced antibody-dependent cellular cytotoxicity plays a prominent role in inhibiting tumorigenesis, even of tumor cells insensitive to EGFR signaling inhibition Journal of Immunology. 187: 3383-3390. PMID 21832160 DOI: 10.4049/jimmunol.1003926  0.325
2011 Lammerts van Bueren JJ, Rispens T, Verploegen S, van der Palen-Merkus T, Stapel S, Workman LJ, James H, van Berkel PH, van de Winkel JG, Platts-Mills TA, Parren PW. Anti-galactose-α-1,3-galactose IgE from allergic patients does not bind α-galactosylated glycans on intact therapeutic antibody Fc domains. Nature Biotechnology. 29: 574-6. PMID 21747378 DOI: 10.1038/nbt.1912  0.309
2011 Klausz K, Berger S, Lammerts van Bueren JJ, Derer S, Lohse S, Dechant M, van de Winkel JG, Peipp M, Parren PW, Valerius T. Complement-mediated tumor-specific cell lysis by antibody combinations targeting epidermal growth factor receptor (EGFR) and its variant III (EGFRvIII). Cancer Science. 102: 1761-8. PMID 21718386 DOI: 10.1111/j.1349-7006.2011.02019.x  0.401
2011 Peipp M, van de Winkel JG, Valerius T. Molecular engineering to improve antibodies' anti-lymphoma activity. Best Practice & Research. Clinical Haematology. 24: 217-29. PMID 21658620 DOI: 10.1016/j.beha.2011.03.004  0.447
2011 Lohse S, Derer S, Beyer T, Klausz K, Peipp M, Leusen JH, van de Winkel JG, Dechant M, Valerius T. Recombinant dimeric IgA antibodies against the epidermal growth factor receptor mediate effective tumor cell killing. Journal of Immunology (Baltimore, Md. : 1950). 186: 3770-8. PMID 21317397 DOI: 10.4049/jimmunol.1003082  0.423
2010 van der Poel CE, Karssemeijer RA, Boross P, van der Linden JA, Blokland M, van de Winkel JG, Leusen JH. Cytokine-induced immune complex binding to the high-affinity IgG receptor, FcγRI, in the presence of monomeric IgG. Blood. 116: 5327-33. PMID 20805361 DOI: 10.1182/blood-2010-04-280214  0.357
2010 de Haij S, Jansen JH, Boross P, Beurskens FJ, Bakema JE, Bos DL, Martens A, Verbeek JS, Parren PW, van de Winkel JG, Leusen JH. In vivo cytotoxicity of type I CD20 antibodies critically depends on Fc receptor ITAM signaling. Cancer Research. 70: 3209-17. PMID 20354182 DOI: 10.1158/0008-5472.CAN-09-4109  0.349
2010 Schneider-Merck T, Van Lammerts Bueren JJ, Berger S, Rossen K, Van Berkel PHC, Derer S, Beyer T, Lohse S, Bleeker WK, Peipp M, Parren PWHI, Van De Winkel JGJ, Valerius T, Dechant M. Human IgG2 antibodies against epidermal growth factor receptor effectively trigger antibody-dependent cellular cytotoxicity but, in contrast to IgG1, only by cells of myeloid lineage Journal of Immunology. 184: 512-520. PMID 19949082 DOI: 10.4049/jimmunol.0900847  0.344
2010 van de Winkel JG. Fc receptors: role in biology and antibody therapy. Immunology Letters. 128: 4-5. PMID 19808048 DOI: 10.1016/j.imlet.2009.09.005  0.44
2010 van Berkel PH, Gerritsen J, van Voskuilen E, Perdok G, Vink T, van de Winkel JG, Parren PW. Rapid production of recombinant human IgG With improved ADCC effector function in a transient expression system. Biotechnology and Bioengineering. 105: 350-7. PMID 19739094 DOI: 10.1002/bit.22535  0.352
2009 Labrijn AF, Buijsse AO, van den Bremer ET, Verwilligen AY, Bleeker WK, Thorpe SJ, Killestein J, Polman CH, Aalberse RC, Schuurman J, van de Winkel JG, Parren PW. Therapeutic IgG4 antibodies engage in Fab-arm exchange with endogenous human IgG4 in vivo. Nature Biotechnology. 27: 767-71. PMID 19620983 DOI: 10.1038/Nbt.1553  0.453
2009 van Berkel PH, Gerritsen J, Perdok G, Valbjørn J, Vink T, van de Winkel JG, Parren PW. N-linked glycosylation is an important parameter for optimal selection of cell lines producing biopharmaceutical human IgG. Biotechnology Progress. 25: 244-51. PMID 19224598 DOI: 10.1002/btpr.92  0.327
2008 Beurskens FJ, Ruuls SR, Engelberts PJ, Vink T, Mackus WJ, van de Winkel JG, Parren PW. Complement activation impacts B-cell depletion by both type I and type II CD20 monoclonal antibodies. Blood. 112: 4354-5; author reply. PMID 18988880 DOI: 10.1182/blood-2008-07-171082  0.311
2008 Ruuls SR, Lammerts van Bueren JJ, van de Winkel JG, Parren PW. Novel human antibody therapeutics: the age of the Umabs. Biotechnology Journal. 3: 1157-71. PMID 18702090 DOI: 10.1002/biot.200800110  0.465
2008 Dechant M, Weisner W, Berger S, Peipp M, Beyer T, Schneider-Merck T, Lammerts Van Bueren JJ, Bleeker WK, Parren PWHI, Van De Winkel JGJ, Valerius T. Complement-dependent tumor cell lysis triggered by combinations of epidermal growth factor receptor antibodies Cancer Research. 68: 4998-5003. PMID 18593896 DOI: 10.1158/0008-5472.CAN-07-6226  0.443
2008 Peipp M, Van Bueren JJL, Schneider-Merck T, Bleeker WWK, Dechant M, Beyer T, Repp R, Van Berkel PHC, Vink T, Van De Winkel JGJ, Parren PWHI, Valerius T. Antibody fucosylation differentially impacts cytotoxicity mediated by NK and PMN effector cells Blood. 112: 2390-2399. PMID 18566325 DOI: 10.1182/blood-2008-03-144600  0.481
2008 Bleeker WK, Munk ME, Mackus WJM, Van Den Brakel JHN, Pluyter M, Glennie MJ, Van De Winkel JGJ, Parren PWHI. Estimation of dose requirements for sustained in vivo activity of a therapeutic human anti-CD20 antibody British Journal of Haematology. 140: 303-312. PMID 18045353 DOI: 10.1111/j.1365-2141.2007.06916.x  0.343
2007 Kolfschoten MVDN, Schuurman J, Losen M, Bleeker WK, Martínez-Martínez P, Vermeulen E, Den Bleker TH, Wiegman L, Vink T, Aarden LA, De Baets MH, Van De Winkel JGJ, Aalberse RC, Parren PWHI. Anti-inflammatory activity of human IgG4 antibodies by dynamic Fab arm exchange Science. 317: 1554-1557. PMID 17872445 DOI: 10.1126/science.1144603  0.462
2007 Dechant M, Beyer T, Schneider-Merck T, Weisner W, Peipp M, Van De Winkel JGJ, Valerius T. Effector mechanisms of recombinant IgA antibodies against epidermal growth factor receptor Journal of Immunology. 179: 2936-2943. PMID 17709508  0.342
2007 McIntosh RS, Shi J, Jennings RM, Chappel JC, de Koning-Ward TF, Smith T, Green J, van Egmond M, Leusen JH, Lazarou M, van de Winkel J, Jones TS, Crabb BS, Holder AA, Pleass RJ. The importance of human FcgammaRI in mediating protection to malaria. Plos Pathogens. 3: e72. PMID 17511516 DOI: 10.1371/journal.ppat.0030072  0.37
2007 van Sorge NM, Yuki N, Jansen MD, Nishimoto Y, Susuki K, Wokke JH, van de Winkel JG, van den Berg LH, van der Pol WL. Leukocyte and complement activation by GM1-specific antibodies is associated with acute motor axonal neuropathy in rabbits. Journal of Neuroimmunology. 182: 116-23. PMID 17161468 DOI: 10.1016/J.Jneuroim.2006.10.005  0.624
2007 van Sorge NM, Yuki N, Koga M, Susuki K, Jansen MD, van Kooten C, Wokke JH, van de Winkel JG, van der Pol WL, van den Berg LH. Ganglioside-specific IgG and IgA recruit leukocyte effector functions in Guillain-Barré syndrome. Journal of Neuroimmunology. 182: 177-84. PMID 17156858 DOI: 10.1016/J.Jneuroim.2006.10.015  0.65
2006 Vidarsson G, Stemerding AM, Stapleton NM, Spliethoff SE, Janssen H, Rebers FE, de Haas M, van de Winkel JG. FcRn: an IgG receptor on phagocytes with a novel role in phagocytosis. Blood. 108: 3573-9. PMID 16849638 DOI: 10.1182/blood-2006-05-024539  0.39
2006 Bevaart L, Jansen MJ, van Vugt MJ, Verbeek JS, van de Winkel JG, Leusen JH. The high-affinity IgG receptor, FcgammaRI, plays a central role in antibody therapy of experimental melanoma. Cancer Research. 66: 1261-4. PMID 16452176 DOI: 10.1158/0008-5472.CAN-05-2856  0.433
2006 Steeghs L, van Vliet SJ, Uronen-Hansson H, van Mourik A, Engering A, Sanchez-Hernandez M, Klein N, Callard R, van Putten JP, van der Ley P, van Kooyk Y, van de Winkel JG. Neisseria meningitidis expressing lgtB lipopolysaccharide targets DC-SIGN and modulates dendritic cell function. Cellular Microbiology. 8: 316-25. PMID 16441441 DOI: 10.1111/j.1462-5822.2005.00623.x  0.468
2006 Rodríguez ME, Hellwig SMM, Pérez Vidakovics MLA, Berbers GAM, Van De Winkel JGJ. Bordetella pertussis attachment to respiratory epithelial cells can be impaired by fimbriae-specific antibodies Fems Immunology and Medical Microbiology. 46: 39-47. PMID 16420595 DOI: 10.1111/j.1574-695X.2005.00001.x  0.475
2006 Bevaart L, Goldstein J, Vitale L, Russoniello C, Treml J, Zhang J, Graziano RF, Leusen JH, van de Winkel JG, Keler T. Direct targeting of genetically modified tumour cells to Fc gammaRI triggers potent tumour cytotoxicity. British Journal of Haematology. 132: 317-25. PMID 16409296 DOI: 10.1111/J.1365-2141.2005.05884.X  0.324
2005 Vidarsson G, Overbeeke N, Stemerding AM, van den Dobbelsteen G, van Ulsen P, van der Ley P, Kilian M, van de Winkel JG. Working mechanism of immunoglobulin A1 (IgA1) protease: cleavage of IgA1 antibody to Neisseria meningitidis PorA requires de novo synthesis of IgA1 Protease. Infection and Immunity. 73: 6721-6. PMID 16177349 DOI: 10.1128/IAI.73.10.6721-6726.2005  0.365
2005 Van Royen-Kerkhof A, Sanders EAM, Walraven V, Voorhorst-Ogink M, Saeland E, Teeling JL, Gerritsen A, Van Dijk MA, Kuis W, Rijkers GT, Vitale L, Keler T, McKenzie SE, Leusen JHW, Van De Winkel JGJ. A novel human CD32 mAb blocks experimental immune haemolytic anaemia in FcγRIIA transgenic mice British Journal of Haematology. 130: 130-137. PMID 15982355 DOI: 10.1111/j.1365-2141.2005.05571.x  0.458
2005 Otten MA, Rudolph E, Dechant M, Tuk CW, Reijmers RM, Beelen RH, van de Winkel JG, van Egmond M. Immature neutrophils mediate tumor cell killing via IgA but not IgG Fc receptors. Journal of Immunology (Baltimore, Md. : 1950). 174: 5472-80. PMID 15843545  0.305
2005 Breij EC, Heijnen P, Vloet R, Saito T, van de Winkel JG, Dijkstra CD, Amor S, Verbeek S. The FcRgamma chain is not essential for induction of experimental allergic encephalomyelitis (EAE) or anti-myelin antibody-mediated exacerbation of EAE. Journal of Neuropathology and Experimental Neurology. 64: 304-11. PMID 15835266  0.393
2005 van Sorge NM, van der Pol WL, Jansen MD, Geleijns KP, Kalmijn S, Hughes RA, Rees JH, Pritchard J, Vedeler CA, Myhr KM, Shaw C, van Schaik IN, Wokke JH, van Doorn PA, Jacobs BC, ... van de Winkel JG, et al. Severity of Guillain-Barré syndrome is associated with Fc gamma Receptor III polymorphisms. Journal of Neuroimmunology. 162: 157-64. PMID 15833371 DOI: 10.1016/J.Jneuroim.2005.01.016  0.611
2004 Kobayashi T, Takauchi A, van Spriel AB, Vilé HA, Hayakawa M, Shibata Y, Abiko Y, van de Winkel JG, Yoshie H. Targeting of Porphyromonas gingivalis with a bispecific antibody directed to FcalphaRI (CD89) improves in vitro clearance by gingival crevicular neutrophils. Vaccine. 23: 585-94. PMID 15542178 DOI: 10.1016/j.vaccine.2004.07.015  0.48
2004 Bleeker WK, Lammerts Van Bueren JJ, Van Ojik HH, Gerritsen AF, Pluyter M, Houtkamp M, Halk E, Goldstein J, Schuurman J, Van Dijk MA, Van De Winkel JGJ, Parren PWHI. Dual mode of action of a human anti-epidermal growth factor receptor monoclonal antibody for cancer therapy Journal of Immunology. 173: 4699-4707. PMID 15383606  0.326
2004 Bouts AH, Krediet RT, Davin JC, Monnens LA, Nauta J, Schröder CH, van de Winkel JG, Out TA. IGG and complement receptor expression on peripheral white blood cells in uraemic children. Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association. 19: 2296-301. PMID 15266033 DOI: 10.1093/ndt/gfh402  0.312
2003 Armour KL, van de Winkel JG, Williamson LM, Clark MR. Differential binding to human FcgammaRIIa and FcgammaRIIb receptors by human IgG wildtype and mutant antibodies. Molecular Immunology. 40: 585-93. PMID 14597161  0.401
2003 van Ojik HH, Bevaart L, Dahle CE, Bakker A, Jansen MJ, van Vugt MJ, van de Winkel JG, Weiner GJ. CpG-A and B oligodeoxynucleotides enhance the efficacy of antibody therapy by activating different effector cell populations. Cancer Research. 63: 5595-600. PMID 14500400  0.304
2003 Hellwig SMM, Rodriguez ME, Berbers GAM, Van De Winkel JGJ, Mooi FR. Crucial role of antibodies to pertactin in Bordetella pertussis immunity Journal of Infectious Diseases. 188: 738-742. PMID 12934190 DOI: 10.1086/377283  0.494
2003 Pleass RJ, Ogun SA, McGuinness DH, van de Winkel JG, Holder AA, Woof JM. Novel antimalarial antibodies highlight the importance of the antibody Fc region in mediating protection. Blood. 102: 4424-30. PMID 12855589 DOI: 10.1182/blood-2003-02-0583  0.409
2003 Glennie MJ, van de Winkel JG. Renaissance of cancer therapeutic antibodies. Drug Discovery Today. 8: 503-10. PMID 12818520  0.378
2003 Saeland E, Leusen JHW, Vidarsson G, Kuis W, Sanders EAM, Jonsdottir I, Van De Winkel JGJ. Role of leukocyte immunoglobulin G receptors in vaccine-induced immunity to Streptococcus pneumoniae Journal of Infectious Diseases. 187: 1686-1693. PMID 12751025 DOI: 10.1086/375276  0.354
2003 van Roon JA, van Vuuren AJ, Wijngaarden S, Jacobs KM, Bijlsma JW, Lafeber FP, Thepen T, van de Winkel JG. Selective elimination of synovial inflammatory macrophages in rheumatoid arthritis by an Fcgamma receptor I-directed immunotoxin. Arthritis and Rheumatism. 48: 1229-38. PMID 12746896 DOI: 10.1002/art.10940  0.402
2003 van Sorge NM, van den Berg LH, Geleijns K, van Strijp JA, Jacobs BC, van Doorn PA, Wokke JH, van de Winkel JG, Leusen JH, van der Pol WL. Anti-GM1 IgG antibodies induce leukocyte effector functions via Fcgamma receptors. Annals of Neurology. 53: 570-9. PMID 12730990 DOI: 10.1002/Ana.10503  0.646
2003 van Spriel AB, van Ojik HH, Bakker A, Jansen MJ, van de Winkel JG. Mac-1 (CD11b/CD18) is crucial for effective Fc receptor-mediated immunity to melanoma. Blood. 101: 253-8. PMID 12485936 DOI: 10.1182/blood.V101.1.253  0.355
2002 Dechant M, Vidarsson G, Stockmeyer B, Repp R, Glennie MJ, Gramatzki M, van De Winkel JG, Valerius T. Chimeric IgA antibodies against HLA class II effectively trigger lymphoma cell killing. Blood. 100: 4574-80. PMID 12393717 DOI: 10.1182/blood-2002-03-0687  0.429
Low-probability matches (unlikely to be authored by this person)
2011 Repp R, Kellner C, Muskulus A, Staudinger M, Mohseni Nodehi S, Glorius P, Akramiene D, Dechant M, Fey GH, van Berkel PHC, van de Winkel JGJ, Parren PWHI, Valerius T, Gramatzki M, Peipp M. Combined Fc-protein- and Fc-glyco-engineering of scFv-Fc fusion proteins synergistically enhances CD16a binding but does not further enhance NK-cell mediated ADCC Journal of Immunological Methods. 373: 67-78. PMID 21855548 DOI: 10.1016/j.jim.2011.08.003  0.299
2008 Lammerts van Bueren JJ, Bleeker WK, Brännström A, von Euler A, Jansson M, Peipp M, Schneider-Merck T, Valerius T, van de Winkel JG, Parren PW. The antibody zalutumumab inhibits epidermal growth factor receptor signaling by limiting intra- and intermolecular flexibility. Proceedings of the National Academy of Sciences of the United States of America. 105: 6109-14. PMID 18427122 DOI: 10.1073/pnas.0709477105  0.298
2001 Monteiro RC, Van De Winkel JG. IgA Fc receptors. Annual Review of Immunology. 21: 177-204. PMID 12524384 DOI: 10.1146/annurev.immunol.21.120601.141011  0.295
2003 Saeland E, Vidarsson G, Leusen JH, Van Garderen E, Nahm MH, Vile-Weekhout H, Walraven V, Stemerding AM, Verbeek JS, Rijkers GT, Kuis W, Sanders EA, Van De Winkel JG. Central role of complement in passive protection by human IgG1 and IgG2 anti-pneumococcal antibodies in mice. Journal of Immunology (Baltimore, Md. : 1950). 170: 6158-64. PMID 12794146 DOI: 10.4049/Jimmunol.170.12.6158  0.292
2003 Parren PW, Leusen JH, van de Winkel JG. Antibody-catalyzed water oxidation: state-of-the-art immunity or ancient history? Trends in Immunology. 24: 467-9. PMID 12967665  0.29
2004 Bevaart L, Van Ojik HH, Sun AW, Sulahian TH, Leusen JH, Weiner GJ, Van De Winkel JG, Van Vugt MJ. CpG oligodeoxynucleotides enhance FcgammaRI-mediated cross presentation by dendritic cells. International Immunology. 16: 1091-8. PMID 15192052 DOI: 10.1093/intimm/dxh110  0.287
2006 Van Lammerts Bueren JJ, Bleeker WK, Bøgh HO, Houtkamp M, Schuurman J, Van De Winkel JGJ, Parren PWHI. Effect of target dynamics on pharmacokinetics of a novel therapeutic antibody against the epidermal growth factor receptor: Implications for the mechanisms of action Cancer Research. 66: 7630-7638. PMID 16885363 DOI: 10.1158/0008-5472.CAN-05-4010  0.284
2004 Teeling JL, French RR, Cragg MS, van den Brakel J, Pluyter M, Huang H, Chan C, Parren PW, Hack CE, Dechant M, Valerius T, van de Winkel JG, Glennie MJ. Characterization of new human CD20 monoclonal antibodies with potent cytolytic activity against non-Hodgkin lymphomas. Blood. 104: 1793-800. PMID 15172969 DOI: 10.1182/blood-2004-01-0039  0.281
2011 van der Poel CE, Spaapen RM, van de Winkel JG, Leusen JH. Functional characteristics of the high affinity IgG receptor, FcγRI. Journal of Immunology (Baltimore, Md. : 1950). 186: 2699-704. PMID 21325219 DOI: 10.4049/jimmunol.1003526  0.279
2016 Engelberts PJ, Voorhorst M, Schuurman J, van Meerten T, Bakker JM, Vink T, Mackus WJ, Breij EC, Derer S, Valerius T, van de Winkel JG, Parren PW, Beurskens FJ. Type I CD20 Antibodies Recruit the B Cell Receptor for Complement-Dependent Lysis of Malignant B Cells. Journal of Immunology (Baltimore, Md. : 1950). 197: 4829-4837. PMID 27807190 DOI: 10.4049/jimmunol.1600811  0.277
2004 Wijngaarden S, van de Winkel JG, Jacobs KM, Bijlsma JW, Lafeber FP, van Roon JA. A shift in the balance of inhibitory and activating Fcgamma receptors on monocytes toward the inhibitory Fcgamma receptor IIb is associated with prevention of monocyte activation in rheumatoid arthritis. Arthritis and Rheumatism. 50: 3878-87. PMID 15593228 DOI: 10.1002/art.20672  0.275
2008 Bakema JE, Bakker A, de Haij S, Honing H, Bracke M, Koenderman L, Vidarsson G, van de Winkel JG, Leusen JH. Inside-out regulation of Fc alpha RI (CD89) depends on PP2A. Journal of Immunology (Baltimore, Md. : 1950). 181: 4080-8. PMID 18768864  0.274
2001 Kobayashi T, Yamamoto K, Sugita N, van der Pol WL, Yasuda K, Kaneko S, van de Winkel JGJ, Yoshie H. The Fcγ Receptor Genotype as a Severity Factor for Chronic Periodontitis in Japanese Patients. Journal of Periodontology. 72: 1324-1331. PMID 29537533 DOI: 10.1902/jop.2001.72.10.1324  0.266
2003 Breij EC, van der Pol WL, van Winsen L, Jansen MD, Dijkstra CD, van de Winkel JG, Uitdehaag BM. No association of Fc gamma RIIa, Fc gamma RIIIa and Fc gamma RIIIb polymorphisms with MS. Journal of Neuroimmunology. 140: 210-5. PMID 12864991  0.265
2012 Otten MA, Bakema JE, Tuk CW, Glennie MJ, Tutt AL, Beelen RH, van de Winkel JG, van Egmond M. Enhanced FcαRI-mediated neutrophil migration towards tumour colonies in the presence of endothelial cells. European Journal of Immunology. 42: 1815-21. PMID 22535639 DOI: 10.1002/eji.201141982  0.252
2002 Van Spriel AB, Leusen JH, Vilé H, Van De Winkel JG. Mac-1 (CD11b/CD18) as accessory molecule for Fc alpha R (CD89) binding of IgA. Journal of Immunology (Baltimore, Md. : 1950). 169: 3831-6. PMID 12244179 DOI: 10.4049/jimmunol.169.7.3831  0.249
2009 Pawluczkowycz AW, Beurskens FJ, Beum PV, Lindorfer MA, van de Winkel JG, Parren PW, Taylor RP. Binding of submaximal C1q promotes complement-dependent cytotoxicity (CDC) of B cells opsonized with anti-CD20 mAbs ofatumumab (OFA) or rituximab (RTX): considerably higher levels of CDC are induced by OFA than by RTX. Journal of Immunology (Baltimore, Md. : 1950). 183: 749-58. PMID 19535640 DOI: 10.4049/Jimmunol.0900632  0.238
2006 Otten MA, Groenveld I, van de Winkel JG, van Egmond M. Inefficient antigen presentation via the IgA Fc receptor (FcalphaRI) on dendritic cells. Immunobiology. 211: 503-10. PMID 16920489 DOI: 10.1016/j.imbio.2006.05.016  0.237
2000 Kobayashi T, Sugita N, van der Pol WL, Nunokawa Y, Westerdaal NAC, Yamamoto K, Van De Winkel JGJ, Yoshie H. The Fcγ Receptor Genotype as a Risk Factor for Generalized Early-Onset Periodontitis in Japanese Patients. Journal of Periodontology. 71: 1425-1432. PMID 29537526 DOI: 10.1902/jop.2000.71.9.1425  0.229
2004 Beekman JM, Bakema JE, van der Linden J, Tops B, Hinten M, van Vugt M, van de Winkel JG, Leusen JH. Modulation of FcgammaRI (CD64) ligand binding by blocking peptides of periplakin. The Journal of Biological Chemistry. 279: 33875-81. PMID 15161926 DOI: 10.1074/jbc.M401018200  0.227
2006 Teeling JL, Mackus WJ, Wiegman LJ, van den Brakel JH, Beers SA, French RR, van Meerten T, Ebeling S, Vink T, Slootstra JW, Parren PW, Glennie MJ, van de Winkel JG. The biological activity of human CD20 monoclonal antibodies is linked to unique epitopes on CD20. Journal of Immunology (Baltimore, Md. : 1950). 177: 362-71. PMID 16785532  0.226
2003 Arigita C, Bevaart L, Everse LA, Koning GA, Hennink WE, Crommelin DJ, van de Winkel JG, van Vugt MJ, Kersten GF, Jiskoot W. Liposomal meningococcal B vaccination: role of dendritic cell targeting in the development of a protective immune response. Infection and Immunity. 71: 5210-8. PMID 12933866  0.225
2011 Beum PV, Lindorfer MA, Peek EM, Stukenberg PT, de Weers M, Beurskens FJ, Parren PW, van de Winkel JG, Taylor RP. Penetration of antibody-opsonized cells by the membrane attack complex of complement promotes Ca(2+) influx and induces streamers. European Journal of Immunology. 41: 2436-46. PMID 21674476 DOI: 10.1002/Eji.201041204  0.223
2012 Lammerts van Bueren JJ, Bleeker WK, Brännström A, Jansson M, Peipp M, Schneider-Merck T, Valerius T, van de Winkel JGJ, Parren PWHI. Retraction for Lammerts van Bueren et al. The antibody zalutumumab inhibits epidermal growth factor receptor signaling by limiting intra- and intermolecular flexibility. Proceedings of the National Academy of Sciences of the United States of America. 109: 5548. PMID 22431606  0.222
2005 Bouts AH, Davin JC, Krediet RT, Schröder CH, Monnens LA, Nauta J, van de Winkel JG, Out TA. IgG and complement receptor expression in children treated by peritoneal dialysis. Pediatric Nephrology (Berlin, Germany). 20: 1161-7. PMID 15856320 DOI: 10.1007/s00467-005-1850-8  0.213
2006 van Vuuren AJ, van Roon JA, Walraven V, Stuij I, Harmsen MC, McLaughlin PM, van de Winkel JG, Thepen T. CD64-directed immunotoxin inhibits arthritis in a novel CD64 transgenic rat model. Journal of Immunology (Baltimore, Md. : 1950). 176: 5833-8. PMID 16670289  0.213
2004 Tacken PJ, Hartshorn KL, White MR, van Kooten C, van de Winkel JG, Reid KB, Batenburg JJ. Effective targeting of pathogens to neutrophils via chimeric surfactant protein D/anti-CD89 protein. Journal of Immunology (Baltimore, Md. : 1950). 172: 4934-40. PMID 15067073 DOI: 10.4049/Jimmunol.172.8.4934  0.209
2010 van Meerten T, Rozemuller H, Hol S, Moerer P, Zwart M, Hagenbeek A, Mackus WJ, Parren PW, van de Winkel JG, Ebeling SB, Martens AC. HuMab-7D8, a monoclonal antibody directed against the membrane-proximal small loop epitope of CD20 can effectively eliminate CD20 low expressing tumor cells that resist rituximab-mediated lysis. Haematologica. 95: 2063-71. PMID 20851867 DOI: 10.3324/Haematol.2010.025783  0.208
2004 Beekman JM, Bakema JE, van de Winkel JG, Leusen JH. Direct interaction between FcgammaRI (CD64) and periplakin controls receptor endocytosis and ligand binding capacity. Proceedings of the National Academy of Sciences of the United States of America. 101: 10392-7. PMID 15229321 DOI: 10.1073/pnas.0401217101  0.208
2008 Otten MA, van der Bij GJ, Verbeek SJ, Nimmerjahn F, Ravetch JV, Beelen RH, van de Winkel JG, van Egmond M. Experimental antibody therapy of liver metastases reveals functional redundancy between Fc gammaRI and Fc gammaRIV. Journal of Immunology (Baltimore, Md. : 1950). 181: 6829-36. PMID 18981101  0.207
2010 Bakema JE, Hiemstra IH, Bakker J, de Haij S, Kok Y, Adema G, van Egmond M, Coffer PJ, van de Winkel JG, Leusen JH. c-Jun activating binding protein 1 binds to the IgA receptor and modulates protein levels of FcalphaRI and FcRgamma-chain. European Journal of Immunology. 40: 2035-40. PMID 20411563 DOI: 10.1002/Eji.200939985  0.206
2003 Villadsen LS, Schuurman J, Beurskens F, Dam TN, Dagnaes-Hansen F, Skov L, Rygaard J, Voorhorst-Ogink MM, Gerritsen AF, van Dijk MA, Parren PW, Baadsgaard O, van de Winkel JG. Resolution of psoriasis upon blockade of IL-15 biological activity in a xenograft mouse model. The Journal of Clinical Investigation. 112: 1571-80. PMID 14617758 DOI: 10.1172/JCI18986  0.205
2011 Beum PV, Peek EM, Lindorfer MA, Beurskens FJ, Engelberts PJ, Parren PW, van de Winkel JG, Taylor RP. Loss of CD20 and bound CD20 antibody from opsonized B cells occurs more rapidly because of trogocytosis mediated by Fc receptor-expressing effector cells than direct internalization by the B cells. Journal of Immunology (Baltimore, Md. : 1950). 187: 3438-47. PMID 21841127 DOI: 10.4049/Jimmunol.1101189  0.202
2003 van Roon J, Wijngaarden S, Lafeber FP, Damen C, van de Winkel J, Bijlsma JW. Interleukin 10 treatment of patients with rheumatoid arthritis enhances Fc gamma receptor expression on monocytes and responsiveness to immune complex stimulation. The Journal of Rheumatology. 30: 648-51. PMID 12672180  0.201
2005 Leemans JC, Thepen T, Weijer S, Florquin S, van Rooijen N, van de Winkel JG, van der Poll T. Macrophages play a dual role during pulmonary tuberculosis in mice. The Journal of Infectious Diseases. 191: 65-74. PMID 15593005 DOI: 10.1086/426395  0.197
2011 de Weers M, Tai YT, van der Veer MS, Bakker JM, Vink T, Jacobs DC, Oomen LA, Peipp M, Valerius T, Slootstra JW, Mutis T, Bleeker WK, Anderson KC, Lokhorst HM, van de Winkel JG, et al. Daratumumab, a novel therapeutic human CD38 monoclonal antibody, induces killing of multiple myeloma and other hematological tumors. Journal of Immunology (Baltimore, Md. : 1950). 186: 1840-8. PMID 21187443 DOI: 10.4049/jimmunol.1003032  0.193
2003 Tur MK, Huhn M, Thepen T, Stöcker M, Krohn R, Vogel S, Jost E, Osieka R, van de Winkel JG, Fischer R, Finnern R, Barth S. Recombinant CD64-specific single chain immunotoxin exhibits specific cytotoxicity against acute myeloid leukemia cells. Cancer Research. 63: 8414-9. PMID 14679004  0.185
2004 Steeghs L, Tommassen J, Leusen JH, van de Winkel JG, van der Ley P. Teasing apart structural determinants of 'toxicity' and 'adjuvanticity': implications for meningococcal vaccine development. Journal of Endotoxin Research. 10: 113-9. PMID 15120002 DOI: 10.1179/096805104225004059  0.179
2003 van der Pol WL, Jansen MD, Sluiter WJ, van de Sluis B, Leppers-van de Straat FG, Kobayashi T, Westendorp RG, Huizinga TW, van de Winkel JG. Evidence for non-random distribution of Fcgamma receptor genotype combinations. Immunogenetics. 55: 240-6. PMID 12830330 DOI: 10.1007/s00251-003-0574-9  0.178
2011 Rose RJ, Labrijn AF, van den Bremer ET, Loverix S, Lasters I, van Berkel PH, van de Winkel JG, Schuurman J, Parren PW, Heck AJ. Quantitative analysis of the interaction strength and dynamics of human IgG4 half molecules by native mass spectrometry. Structure (London, England : 1993). 19: 1274-82. PMID 21893287 DOI: 10.1016/J.Str.2011.06.016  0.177
2012 Derer S, Berger S, Schlaeth M, Schneider-Merck T, Klausz K, Lohse S, Overdijk MB, Dechant M, Kellner C, Nagelmeier I, Scheel AH, van Bueren JJL, van de Winkel JGJ, Parren PWHI, Peipp M, et al. Oncogenic KRAS impairs EGFR antibodies' efficiency by C/EBPβ-dependent suppression of EGFR expression Neoplasia. 14: 190-205. PMID 22496619 DOI: 10.1593/neo.111636  0.172
2006 Bakema JE, de Haij S, den Hartog-Jager CF, Bakker J, Vidarsson G, van Egmond M, van de Winkel JG, Leusen JH. Signaling through mutants of the IgA receptor CD89 and consequences for Fc receptor gamma-chain interaction. Journal of Immunology (Baltimore, Md. : 1950). 176: 3603-10. PMID 16517729  0.171
2008 Beum PV, Lindorfer MA, Beurskens F, Stukenberg PT, Lokhorst HM, Pawluczkowycz AW, Parren PW, van de Winkel JG, Taylor RP. Complement activation on B lymphocytes opsonized with rituximab or ofatumumab produces substantial changes in membrane structure preceding cell lysis. Journal of Immunology (Baltimore, Md. : 1950). 181: 822-32. PMID 18566448 DOI: 10.4049/Jimmunol.181.1.822  0.168
2008 Skov L, Beurskens FJ, Zachariae CO, Reitamo S, Teeling J, Satijn D, Knudsen KM, Boot EP, Hudson D, Baadsgaard O, Parren PW, van de Winkel JG. IL-8 as antibody therapeutic target in inflammatory diseases: reduction of clinical activity in palmoplantar pustulosis. Journal of Immunology (Baltimore, Md. : 1950). 181: 669-79. PMID 18566434  0.163
2011 Labrijn AF, Rispens T, Meesters J, Rose RJ, den Bleker TH, Loverix S, van den Bremer ET, Neijssen J, Vink T, Lasters I, Aalberse RC, Heck AJ, van de Winkel JG, Schuurman J, Parren PW. Species-specific determinants in the IgG CH3 domain enable Fab-arm exchange by affecting the noncovalent CH3-CH3 interaction strength. Journal of Immunology (Baltimore, Md. : 1950). 187: 3238-46. PMID 21841137 DOI: 10.4049/Jimmunol.1003336  0.161
2005 van der Straaten HM, Fijnheer R, Nieuwenhuis HK, van de Winkel JG, Verdonck LF. The FcgammaRIIa-polymorphic site as a potential target for acute graft-versus-host disease in allogeneic stem cell transplantation. Biology of Blood and Marrow Transplantation : Journal of the American Society For Blood and Marrow Transplantation. 11: 206-12. PMID 15744239 DOI: 10.1016/j.bbmt.2004.12.331  0.158
2009 Raaz D, Herrmann M, Ekici AB, Klinghammer L, Lausen B, Voll RE, Leusen JH, van de Winkel JG, Daniel WG, Reis A, Garlichs CD. FcgammaRIIa genotype is associated with acute coronary syndromes as first manifestation of coronary artery disease. Atherosclerosis. 205: 512-6. PMID 19232413 DOI: 10.1016/j.atherosclerosis.2009.01.013  0.154
2002 Kyogoku C, Dijstelbloem HM, Tsuchiya N, Hatta Y, Kato H, Yamaguchi A, Fukazawa T, Jansen MD, Hashimoto H, van de Winkel JG, Kallenberg CG, Tokunaga K. Fcgamma receptor gene polymorphisms in Japanese patients with systemic lupus erythematosus: contribution of FCGR2B to genetic susceptibility. Arthritis and Rheumatism. 46: 1242-54. PMID 12115230 DOI: 10.1002/art.10257  0.152
2012 Raaz-Schrauder D, Ekici AB, Munoz LE, Klinghammer L, Voll RE, Leusen JH, van de Winkel JG, Reis A, Schett G, Garlichs CD, Herrmann M. Patients with unstable angina pectoris show an increased frequency of the Fc gamma RIIa R131 allele. Autoimmunity. 45: 556-64. PMID 22559288 DOI: 10.3109/08916934.2012.682665  0.151
2012 Kellner C, Maurer T, Hallack D, Repp R, van de Winkel JG, Parren PW, Valerius T, Humpe A, Gramatzki M, Peipp M. Mimicking an induced self phenotype by coating lymphomas with the NKp30 ligand B7-H6 promotes NK cell cytotoxicity. Journal of Immunology (Baltimore, Md. : 1950). 189: 5037-46. PMID 23066150 DOI: 10.4049/jimmunol.1201321  0.15
2002 Dijstelbloem HM, Hepkema BG, Kallenberg CG, van der Linden MW, Keijsers V, Huizinga TW, Jansen MD, van de Winkel JG. The R-H polymorphism of FCgamma receptor IIa as a risk factor for systemic lupus erythematosus is independent of single-nucleotide polymorphisms in the interleukin-10 gene promoter. Arthritis and Rheumatism. 46: 1125-6. PMID 11953994 DOI: 10.1002/art.518  0.143
2011 Shi J, McIntosh RS, Adame-Gallegos J, Dehal PK, van Egmond M, van de Winkel J, Draper SJ, Forbes EK, Corran PH, Holder AA, Woof JM, Pleass RJ. The generation and evaluation of recombinant human IgA specific for Plasmodium falciparum merozoite surface protein 1-19 (PfMSP1 19). Bmc Biotechnology. 11: 77. PMID 21781305 DOI: 10.1186/1472-6750-11-77  0.14
2003 Stassen MH, Meng F, Melgert E, Machiels BM, Im SH, Fuchs S, Gerritsen AF, van Dijk MA, van de Winkel JG, De Baets MH. Experimental autoimmune myasthenia gravis in mice expressing human immunoglobulin loci. Journal of Neuroimmunology. 135: 56-61. PMID 12576224  0.138
2005 Baslund B, Tvede N, Danneskiold-Samsoe B, Larsson P, Panayi G, Petersen J, Petersen LJ, Beurskens FJ, Schuurman J, van de Winkel JG, Parren PW, Gracie JA, Jongbloed S, Liew FY, McInnes IB. Targeting interleukin-15 in patients with rheumatoid arthritis: a proof-of-concept study. Arthritis and Rheumatism. 52: 2686-92. PMID 16142748 DOI: 10.1002/art.21249  0.132
2007 Otten MA, Leusen JH, Rudolph E, van der Linden JA, Beelen RH, van de Winkel JG, van Egmond M. FcR gamma-chain dependent signaling in immature neutrophils is mediated by FcalphaRI, but not by FcgammaRI. Journal of Immunology (Baltimore, Md. : 1950). 179: 2918-24. PMID 17709506  0.121
2008 Peipp M, Schneider-Merck T, Dechant M, Beyer T, Van Bueren JJL, Bleeker WK, Parren PWHI, Van De Winkel JGJ, Valerius T. Tumor cell killing mechanisms of epidermal growth factor receptor (EGFR) antibodies are not affected by lung cancer-associated EGFR kinase mutations Journal of Immunology. 180: 4338-4345. PMID 18322248  0.117
2008 Beekman JM, Bakema JE, van der Poel CE, van der Linden JA, van de Winkel JG, Leusen JH. Protein 4.1G binds to a unique motif within the Fc gamma RI cytoplasmic tail. Molecular Immunology. 45: 2069-75. PMID 18023480 DOI: 10.1016/j.molimm.2007.10.024  0.086
2004 van Royen-Kerkhof A, Sanders EA, Wijngaarden S, van Roon JA, Voorhorst-Ogink M, Walraven V, Gerritsen A, van Dijk MA, Kuis W, Rijkers GT, Keler T, Leusen JH, van de Winkel JG. Flow cytometric determination of FcgammaRIIa (CD32) polymorphism. Journal of Immunological Methods. 294: 135-44. PMID 15604023 DOI: 10.1016/j.jim.2004.09.010  0.076
2008 Beekman JM, van der Linden JA, van de Winkel JG, Leusen JH. FcgammaRI (CD64) resides constitutively in lipid rafts. Immunology Letters. 116: 149-55. PMID 18207250 DOI: 10.1016/j.imlet.2007.12.003  0.07
2008 Beekman JM, van der Poel CE, van der Linden JA, van den Berg DL, van den Berghe PV, van de Winkel JG, Leusen JH. Filamin A stabilizes Fc gamma RI surface expression and prevents its lysosomal routing. Journal of Immunology (Baltimore, Md. : 1950). 180: 3938-45. PMID 18322202  0.052
2008 Parren PW, van de Winkel JG. An integrated science-based approach to drug development. Current Opinion in Immunology. 20: 426-30. PMID 18602995 DOI: 10.1016/j.coi.2008.06.006  0.01
Hide low-probability matches.